GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rezolute Inc (NAS:RZLT) » Definitions » Return-on-Tangible-Equity

Rezolute (Rezolute) Return-on-Tangible-Equity : -83.89% (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Rezolute Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Rezolute's annualized net income for the quarter that ended in Mar. 2024 was $-68.20 Mil. Rezolute's average shareholder tangible equity for the quarter that ended in Mar. 2024 was $81.29 Mil. Therefore, Rezolute's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was -83.89%.

The historical rank and industry rank for Rezolute's Return-on-Tangible-Equity or its related term are showing as below:

RZLT' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -1331.34   Med: -168.62   Max: -38.99
Current: -57.11

During the past 12 years, Rezolute's highest Return-on-Tangible-Equity was -38.99%. The lowest was -1,331.34%. And the median was -168.62%.

RZLT's Return-on-Tangible-Equity is ranked worse than
55.26% of 1303 companies
in the Biotechnology industry
Industry Median: -46.56 vs RZLT: -57.11

Rezolute Return-on-Tangible-Equity Historical Data

The historical data trend for Rezolute's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rezolute Return-on-Tangible-Equity Chart

Rezolute Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - -447.47 -124.92 -46.77 -38.99

Rezolute Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -46.68 -41.82 -52.88 -56.98 -83.89

Competitive Comparison of Rezolute's Return-on-Tangible-Equity

For the Biotechnology subindustry, Rezolute's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Rezolute's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rezolute's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Rezolute's Return-on-Tangible-Equity falls into.



Rezolute Return-on-Tangible-Equity Calculation

Rezolute's annualized Return-on-Tangible-Equity for the fiscal year that ended in Jun. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Jun. 2023 )  (A: Jun. 2022 )(A: Jun. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Jun. 2023 )  (A: Jun. 2022 )(A: Jun. 2023 )
=-51.787/( (149.471+116.172 )/ 2 )
=-51.787/132.8215
=-38.99 %

Rezolute's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-68.2/( (91.728+70.861)/ 2 )
=-68.2/81.2945
=-83.89 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Rezolute  (NAS:RZLT) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Rezolute Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Rezolute's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Rezolute (Rezolute) Business Description

Industry
Traded in Other Exchanges
N/A
Address
275 Shoreline Drive, Suite 500, Redwood City, CA, USA, 94065
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402.
Executives
Brian Kenneth Roberts officer: Chief Medical Officer C/O REZOLUTE, INC., 201 REDWOOD SHORES PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Gil M Labrucherie director 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Wladimir Hogenhuis director 60 LEVERONI COURT, NOVATO CA 94949
Nerissa Kreher director C/O AVROBIO, INC., ONE KENDALL SQ., BLDG. 300, STE. 201, CAMBRIDGE MA 02139
Handok, Inc. 10 percent owner 132, TEHERAN-RO, GANGNAM GU, SOUL M5 06235
Philippe Fauchet director C/O REZOLUTE, INC., 201 REDWOOD SHORES PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Junghee Lim director C/O REZOLUTE, INC., 201 REDWOOD SHORE'S PARKWAY, SUITE 315, REDWOOD CITY CA 94065
Genexine Inc. 10 percent owner 700 DAEWANGPANGYO-RO, KOREA PARKBLDG. B, BUNDANG-GU, SEONGNAM-SI, GYEONGGI-DO M5 13488
Seline E. Miller officer: VP Finance & CAO C/O REZOLUTE, INC., 1450 INFINITE DRIVE, LOUISVILLE CO 80027
Young-jin Kim director 49, BONGEUNSA-RO 49-GIL, GANGNAM-GU, SEOUL M5 06100
Young Chul Sung director 101DONG 404HO, PARKTOWER APT. 69, SEOBINGGO-RO, YONGSAN-GU, SEOUL M5 04385
Keith A. Vendola officer: Chief Financial Officer 111 LIVORNO WAY, REDWOOD CITY CA 94065
Xoma Corp 10 percent owner 2200 POWELL STREET, SUITE 310, EMERYVILLE CA 94608
David F Welch director C/O INFINERA CORPORATION, 140 CASPIAN COURT, SUNNYVALE CA 94089
Morgan Fields officer: Chief Accounting Officer 890 SANTA CRUZ AVE., MENLO PARK CA 94025